At Lycera, we are pioneering innovative approaches to novel oral medicines for treating autoimmune diseases with high unmet medical need. Lycera is targeting two novel autoimmune pathways to develop new classes of small molecules to treat immune disorders such as rheumatoid arthritis, multiple sclerosis, psoriasis and inflammatory bowel disease. Lycera’s world-class team and biological insights in the immunology and inflammation arenas uniquely position the company to realize the promise of translating cutting-edge science into first-in-class oral therapies.